Reid M Huber bought $499k of RAPP
director at Rapport Therapeutics, Inc.. 20,400 shares at an average of $24.48, traded Sep 12, 2025, filed Sep 15, 2025.
Score components
- +15RoleDirector
- +18Trade size$499k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +4Price context24% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.2%, 3m +19.7%, 6m +11.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-203540, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 12, 2025 | POpen-market purchase Common Stock | +20,400 | $24.48 | $499k | 20,400 | Sep 15, 2025 |
Related signals
Other insiders at Rapport Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $143k 4,522 shares | -1% | |
| 23Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $332k 10,000 shares | -7% | |
| 22Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $87k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $374k 8,210 shares | -2% | |
| 13Weak | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. owner | $744k 18,572 shares | -0% | |
| 17Weak | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. owner | $5.4M 133,618 shares | -2% | |
| 17Weak | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. owner | $11M 276,513 shares | -4% | |
| 25Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $809k 20,225 shares | -8% | |
| 25Weak | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. owner | $17M 426,005 shares | -6% | |
| 31Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $696k 19,865 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.